Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), also known as Olema Oncology, is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of targeted therapies for women's cancers. Headquartered in San Francisco with operations in Cambridge, Massachusetts, Olema is advancing a pipeline of novel therapies aimed at improving treatment options for women living with cancer. The core focus of the company centers on endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.
Olema's lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). Palazestrant is currently in Phase 3 clinical trials under the OPERA-01 study for patients with recurrent, locally advanced, or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This innovative therapy has demonstrated significant potential by completely blocking ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer, showing anti-tumor efficacy, favorable pharmacokinetics, CNS penetration, and combinability with CDK4/6 inhibitors.
In addition to palazestrant, Olema is developing a potent KAT6 inhibitor (OP-3136), which addresses an epigenetic target implicated in breast cancer and other cancers. This compound has shown promise in preclinical studies and is expected to move into clinical trials by the end of 2024.
Olema's financial health remains robust, with cash, cash equivalents, and marketable securities totaling $249.0 million as of March 31, 2024. The company reported a net loss of $31.0 million for the first quarter of 2024, primarily driven by increased spending on research and clinical development activities. However, Olema continues to make significant strides in advancing its clinical programs, supported by experienced scientists, healthcare investors, and partnerships with innovative pharmaceutical companies.
Recent corporate highlights include the initiation of a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250, and the selection of a development candidate for the KAT6 program. Olema's commitment to transforming the standard of care for women's cancers is evident in its ongoing clinical studies and presentations at major oncology conferences such as the ESMO Breast Cancer Annual Congress.
For more information about Olema Pharmaceuticals, visit their website at www.olema.com.
On June 2, 2022, Olema Pharmaceuticals granted stock options for 25,400 shares to two new employees under its 2022 Inducement Plan. The options have a grant date of June 1, 2022, with a $2.80 exercise price, matching the last reported sale price. Vested over four years, 25% will vest on the first anniversary, followed by monthly installments. This decision complies with Nasdaq Listing Rule 5635(c)(4). Olema, focused on innovative cancer therapies, is currently evaluating OP-1250 in clinical trials for ER+ breast cancer.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, announced that CEO Sean P. Bohen will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 8:30 a.m. ET. The event will be accessible through a live webcast on Olema’s website, which will remain available for 14 days post-event.
Olema’s lead candidate, OP-1250, is undergoing clinical trials for treating ER-positive, HER2-negative breast cancer.
Olema Pharmaceuticals (Nasdaq: OLMA) announced its Q1 2022 results, highlighting strong progress in clinical trials for its lead candidate, OP-1250. The Phase 1/2 trial continues to enroll patients, with the recommended Phase 2 dose expected by Q2 2022. The company has $267.9 million in cash, sufficient to fund operations into 2024. Despite a net loss of $23 million for the quarter—up from $15.3 million year-over-year—investments in OP-1250 are pivotal for growth. Olema plans to present updated clinical data later this year.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced the granting of stock options for 68,700 shares to three new employees, effective May 2, 2022. The options were approved by the Compensation Committee and are part of the Company's 2022 Inducement Plan. They vest over four years, with an exercise price set at $2.68 per share, equal to the stock's last reported sale price. Olema focuses on targeted therapies for women’s cancers, with its lead candidate, OP-1250, currently in clinical trials for treating ER-positive breast cancer.
Olema Pharmaceuticals (Nasdaq: OLMA) has granted a stock option to a new employee for 20,000 shares of its common stock as part of the 2022 Inducement Plan. The option, effective April 1, 2022, vests over four years, with 25% vesting after the first year and the remaining 75% in monthly installments. The exercise price is set at $4.10 per share, reflecting the last reported sale price on the grant date. This move aligns with Nasdaq Listing Rule 5635(c)(4) aimed at attracting talent.
Olema Pharmaceuticals announced that its CEO, Sean P. Bohen, will participate in a virtual fireside chat at the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 11:30 a.m. ET. The event will be accessible via a live webcast on Olema’s website and archived for 14 days. Olema is focused on targeted therapies for women’s cancers, with its lead candidate, OP-1250, currently in clinical trials for ER-positive breast cancer.
Olema Pharmaceuticals (Nasdaq: OLMA) announces plans to present two posters on nonclinical data for OP-1250 at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022. The first presentation focuses on transcriptional changes in ER+ breast cancer cell lines in response to OP-1250, while the second highlights its efficacy in preventing tumor spread in metastatic ERα+ breast cancer models. OP-1250 is currently undergoing clinical trials in patients with advanced ER-positive breast cancer.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) reported significant progress in clinical studies for OP-1250, targeting ER+ / HER2- breast cancer. Phase 1a data showed favorable pharmacokinetics and encouraging anti-tumor activity in heavily pretreated patients. Enrollment for Phase 1b expansion is on track for completion in Q1 2022, with a Phase 2 study set to begin in H1 2022. The company's financial position is strong, with $287.3 million in cash, sufficient to fund operations into 2024, despite a net loss of $71.1 million for 2021, reflecting increased R&D and G&A expenses.
Olema Pharmaceuticals (Nasdaq: OLMA) announced that CEO Sean P. Bohen will present a corporate overview at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:50 p.m. ET. The presentation can be accessed via a live webcast on Olema's website and will be archived for 14 days. Olema Oncology focuses on developing targeted therapies for women’s cancers, with their lead product candidate, OP-1250, currently in Phase 1/2 trials for treating ER-positive breast cancer.
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) announced the grant of stock options for a total of 270,000 shares to two new employees, effective February 1, 2022. Dr. Naseem Zojwalla received an option for 250,000 shares as the new Chief Medical Officer, while another employee got 20,000 shares. These stock options are part of Olema's 2022 Inducement Plan, vesting over four years with the last reported share price at $7.02. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) to incentivize key hires.
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
What is Olema Pharmaceuticals' primary focus?
What is OP-1250?
What stage is OP-1250 currently in?
What other therapies is Olema developing?
How is Olema's financial health?
Who supports Olema's research and development?
Where is Olema Pharmaceuticals headquartered?
What recent achievements has Olema made?
What is the significance of the OPERA-01 study?
Where can I find more information about Olema Pharmaceuticals?
